Apoptosis in human cancer cells

Current Opinion in Oncology

Volumn 16, Issue 1, 2004, Pages 19-24

  Yu, Jian ^a   Zhang, Lin ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Anticancer therapy; Apoptosis; Cancer Bcl 2 family proteins; Mitochondria

Indexed keywords

BORTEZOMIB; CASPASE; DOXORUBICIN; FLUOROURACIL; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2;

AMINO ACID SEQUENCE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL; CANCER THERAPY; CELL ACTIVITY; CELL STRUCTURE; CELLULAR DISTRIBUTION; DRUG ACTIVITY; DRUG MECHANISM; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MOLECULAR BIOLOGY; MOLECULAR MECHANICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; REVIEW; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; TARGET CELL; TUMOR CELL; CELL TRANSFORMATION; NEOPLASM; PATHOPHYSIOLOGY;

APOPTOSIS; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 2442520504     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200401000-00005     Document Type: Review

References (73)

1. Vogelstein B, Kinzler KW: The genetic basis of human cancer. New York: McGraw-Hill Health Professions Division; 2002.
2. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000, 100:57-70.
3. Aravind L, Dixit VM, Koonin EV: Apoptotic molecular machinery: vastly increased complexity in vertebrates revealed by genome comparisons. Science 2001, 291:1279-1284.
4. Reed JC, Doctor K, Rojas A, et al.: Comparative analysis of apoptosis and inflammation genes of mice and humans. Genome Res 2003, 13:1376-1388. An extensive bioinformatic analysis of the human apoptotic genes and their mouse orthologues that provides an overview of the human apoptotic machinery.
5. Doctor KS, Reed JC, Godzik A, et al.: The apoptosis database. Cell Death Differ 2003, 10:621-633. A useful source of information summarizing the features, tools, and links in the apoptosis database, located at http://www.apoptosis-db.org.
6. Bunz F: Human cell knockouts. Curr Opin Oncol 2002, 14:73-78.
7. Tuschl T: Expanding small RNA interference. Nat Biotechnol 2002, 20:446-448.
8. Jiang X, Kim HE, Shu H, et al.: Distinctive roles of PHAP proteins and prothymosin-alpha in a death regulatory pathway. Science 2003, 299:223-226. An elegant study and the first example of using a chemical genetic approach to identify a novel apoptosis pathway in human cells.
9. Puthalakath H, Strasser A: Keeping killers on a tight leash: transcriptional and post-translational control of the pro-apoptotic activity of BH3-only proteins. Cell Death Differ 2002, 9:505-512.
10. Yin XM, Wang K, Gross A, et al.: Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis. Nature 1999, 400:886-891.
11. Bouillet P, Metcalf D, Huang DC, et al.: Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science 1999, 286:1735-1738.
12. Yu J, Zhang L, Hwang PM, et al.: PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell 2001, 7:673-682.
13. Nakano K, Vousden KH: PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell 2001, 7:683-694.
14. Oda E, Ohki R, Murasawa H, et al.: Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 2000, 288:1053-1058.
15. Danial NN, Gramm CF, Scorrano L, et al.: BAD and glucokinase reside in a mitochondrial complex that integrates glycolysis and apoptosis. Nature 2003, 424:952-956.
16. Cheng EH, Wei MC, Weiler S, et al.: BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol Cell 2001, 8:705-711.
17. Zong WX, Lindsten T, Ross AJ, et al.: BH3-only proteins that bind pro-survival Bcl-2 family members fail to induce apoptosis in the absence of Bax and Bak. Genes Dev 2001, 15:1481-1486.
18. Shangary S, Johnson DE: Peptides derived from BH3 domains of Bcl-2 family members: a comparative analysis of inhibition of Bcl-2, Bcl-x(L) and Bax oligomerization, induction of cytochrome c release, and activation of cell death. Biochemistry (Mosc) 2002, 41:9485-9495.
19. Letai A, Bassik MC, Walensky LD, et al.: Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2002, 2:183-192.
20. Wei MC, Zong WX, Cheng EH, et al.: Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 2001, 292:727-730.
21. Zhang L, Yu J, Park BH, et al.: Role of BAX in the apoptotic response to anticancer agents. Science 2000, 290:989-992.
22. Wang GQ, Gastman BR, Wieckowski E, et al.: A role for mitochondrial Bak in apoptotic response to anticancer drugs. J Biol Chem 2001, 276:34307-34317.
23. Cory S, Adams JM: The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2002, 2:647-656. An excellent review summarizing the function and regulatory mechanisms of the Bcl-2 family proteins.
24. Guo B, Zhai D, Cabezas E, et al.: Humanin peptide suppresses apoptosis by interfering with Bax activation. Nature 2003, 423:456-461. These articles [24•-26•] describe novel regulators of the proapoptotic activities of Bax and Bak.
25. Sawada M, Sun W, Hayes P, et al.: Ku70 suppresses the apoptotic translocation of Bax to mitochondria. Nat Cell Biol 2003, 5:320-329. See [24•].
26. Cheng EH, Sheiko TV, Fisher JK, et al.: VDAC2 inhibits BAK activation and mitochondrial apoptosis. Science 2003, 301:513-517. See [24•].
27. Wang X: The expanding role of mitochondria in apoptosis. Genes Dev 2001, 15:2922-2933.
28. Scorrano L, Oakes SA, Opferman JT, et al.: BAX and BAK regulation of endoplasmic reticulum Ca2+: a control point for apoptosis. Science 2003, 300:135-139. A study defining the endoplasmic reticulum as a new gateway to apoptosis and demonstrating the physiologic links between the mitochondria and endoplasmic reticulum in apoptosis.
29. Zong WX, Li C, Hatzivassiliou G, et al.: Bax and Bak can localize to the endoplasmic reticulum to initiate apoptosis. J Cell Biol 2003, 162:59-69.
30. Yamaguchi H, Bhalla K, Wang HG: Bax plays a pivotal role in thapsigargin-induced apoptosis of human colon cancer HCT116 cells by controlling Smac/Diablo and Omi/HtrA2 release from mitochondria. Cancer Res 2003, 63:1483-1489.
31. Du C, Fang M, Li Y, et al.: Smac, a mitochondrial protein that promotes cytochrome c-dependenl caspase activation by eliminating IAP inhibition. Cell 2000, 102:33-42.
32. Verhagen AM, Ekert PG, Pakusch M, et al.: Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 2000, 102:43-53.
33. Suzuki Y, Imai Y, Nakayama H, et al.: A serine protease, HtrA2, is released from the mitochondria and interacts with XIAP, inducing cell death. Mol Cell 2001, 8:613-621.
34. Joza N, Susin SA, Daugas E, et al.: Essential role of the mitochondrial apoptosis-inducing factor in programmed cell death. Nature 2001, 410:549-554.
35. Wang X, Yang C, Chai J, et al.: Mechanisms of AIF-mediated apoptotic DNA degradation in Caenorhabditis elegans. Science 2002, 298:1587-1592.
36. Marsden VS, O'Connor L, O'Reilly LA, et al.: Apoptosis initiated by Bcl-2-regulated caspase activation independently of the cytochrome c/Apaf 1/caspase-9 apoptosome. Nature 2002, 419:634-637. This article reports the surprising finding that the apoptosome is not required for apoptosis initiation in some cell types.
37. Okada H, Suh WK, Jin J, et al.: Generation and characterization of Smac/DIABLO-deficient mice. Mol Cell Biol 2002, 22:3509-3517.
38. Cryns V, Yuan J: Proteases to die for. Genes Dev 1998, 12:1551-1570.
39. Lassus P, Opitz-Araya X, Lazebnik Y: Requirement for caspase-2 in stress-induced apoptosis before mitochondrial permeabilization. Science 2002, 297:1352-1354. A good example of using the RNA interference method to identify a new role of caspases in apoptosis in human cancer cells
40. Suzuki Y, Nakabayashi Y, Takahashi R: Ubiquitin-protein ligase activity of X-linked inhibitor of apoptosis protein promotes proteasomal degradation of caspase-3 and enhances its anti-apoptotic effect in Fas-induced cell death. Proc Natl Acad Sci U S A 2001, 98:8662-8667.
41. Yang Y, Fang S, Jensen JP, et al.: Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli. Science 2000, 288:874-877.
42. Nijhawan D, Fang M, Traer E, et al.: Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation. Genes Dev 2003, 17:1475-1486.
43. Brune B: Nitric oxide: NO apoptosis or turning it ON? Cell Death Differ 2003, 10:864-869.
44. Deverman BE, Cook BL, Manson SR, et al.: Bcl-xL deamidation is a critical switch in the regulation of the response to DNA damage. Cell 2002, 111:51-62. The first report of deamination as a regulatory mechanism of DN A damage-induced apoptosis.
45. Korsmeyer SJ: BCL-2 gene family and the regulation of programmed cell death. Cancer Res 1999, 59:1693s-1700s.
46. Vogelstein B, Lane D, Levine AJ: Surfing the p53 network. Nature 2000, 408:307-310.
47. Prives C, Hall PA: The p53 pathway. J Pathol 1999, 187:112-126.
48. Yu J, Wang Z, Kinzler KW, et al.: PUMA mediates the apoptotic response to p53 in colorectal cancer cells. Proc Natl Acad Sci U S A 2003, 100:1931-1936. This article provides unequivocal evidence by using the somatic knockout approach that PUMA plays a critical role in p53-mediated apoptosis in human cancer cells.
49. Sax JK, Fei P, Murphy ME, et al.: BID regulation by p53 contributes to chemosensitivity. Nat Cell Biol 2002, 4:842-849.
50. Fei P, Bernhard EJ, El-Deiry WS: Tissue-specific induction of p53 targets in vivo. Cancer Res 2002, 62:7316-7327.
51. Johnstone RW, Ruefli AA, Lowe SW: Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002, 108:153-164.
52. Green DR, Evan GI: A matter of life and death. Cancer Cell 2002, 1:19-30.
53. Reed JC: Apoptosis-targeted therapies for cancer. Cancer Cell 2003, 3:17-22.
54. Velculescu VE, Madden SL, Zhang L, et al.: Analysis of human transcriptomes. Nat Genet 1999, 23:387-388.
55. Lowe SW, Ruley HE, Jacks T, et al.: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993, 74:957-967.
56. Bunz F, Hwang PM, Torrance C, et al.: Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 1999, 104:263-269.
57. Dumont P, Leu JI, Della Pietra AC III, et al.: The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003, 33:357-365. Provocative studies [57•,58•] suggesting a direct and transcription-independent role of p53 in apoptosis induced by chemotherapeutic agents.
58. Mihara M, Erster S, Zaika A, et al.: p53 has a direct apoptogenic role at the mitochondria. Mol Cell 2003, 11:577-590. See [57•].
59. Bergamaschi D, Gasco M, Miller L, et al.: p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 2003, 3:387-402. These articles [59•,60•] demonstrate a connection between p53 and its homologue, p73, in apoptotic response to chemotherapeutic agents.
60. Irwin MS, Kondo K, Marin MC, et al.: Chemosensitivity linked to p73 function. Cancer Cell 2003, 3:403-410. See [59•].
61. LeBlanc H, Lawrence D, Varfolomeev E, et al.: Tumor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat Med 2002, 8:274-281.
62. Amundson SA, Myers TG, Scudiero D, et al.: An informatics approach identifying markers of chemosensitivity in human cancer cell lines. Cancer Res 2000, 60:6101-6110.
63. Soengas MS, Capodieci P, Polsky D, et al.: Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 2001, 409:207-211.
64. Schimmer AD, Pedersen IM, Kitada S, et al.: Functional blocks in caspase activation pathways are common in leukemia and predict patient response to induction chemotherapy. Cancer Res 2003, 63:1242-1248.
65. Garcia-Barros M, Paris F, Cordon-Cardo C, et al.: Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 2003, 300:1155-1159. An interesting study showing that apoptosis of tumor endothelial cells can modulate sensitivity to radiotherapy in xenograft tumors.
66. Degterev A, Lugovskoy A, Cardone M, et al.: Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL. Nat Cell Biol 2001, 3:173-182.
67. Tzung SP, Kim KM, Basanez G, et al.: Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3. Nat Cell Biol 2001, 3:183-191.
68. Shangary S, Johnson DE: Recent advances in the development of anticancer agents targeting cell death inhibitors in the Bcl-2 protein family. Leukemia 2003, 17:1470-1481.
69. Nguyen JT, Wells JA: Direct activation of the apoptosis machinery as a mechanism to target cancer cells. Proc Natl Acad Sci USA 2003, 100:7533-7538.
70. Almasan A, Ashkenazi A: Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev 2003, 14:337-348.
71. Fulda S, Wick W, Weller M, et al.: Smac agonists sensitize for Apo2L/TRAIL-or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med 2002, 8:808-815. This article illustrates the effectiveness of combinatory therapy using death receptor activators and peptides derived from apoptotic proteins for the treatment of tumors in vivo.
72. Guo F, Nimmanapalli R, Paranawithana S, et al.: Ectopic overexpression of second mitochondria-derived activator of caspases (Smac/DIABLO) or cotreatment with N-terminus of Smac/DIABLO peptide potentiates epothilone B derivative-(BMS 247550) and Apo-2L/TRAIL-induced apoptosis. Blood 2002, 99:3419-3426.
73. Paramore A, Frantz S: Bortezomib. Nat Rev Drug Discov 2003, 2:611-612.